Mithra Signs LSA for Commercialization of Myring™ and Tibelia® in Eastern Europe

  • Mithra grants exclusive license to Aicore Life Sciences for commercialization of Myring™ and Tibelia® in Eastern Europe
  • Production of Myring™ at the Mithra CDMO facility in Belgium
  • Agreement follows licensing deals with major international market leaders for commercialization of Myring™
Liege, Belgium, 24 October 2019 – 7:30  CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has entered into two exclusive license and supply agreements with Aicore Life Sciences for the registration and commercialization of two major products in contraception and menopause in Eastern Europe: the hormonal contraceptive ring Myring™ and the tibolone-based product Tibelia® for use in Hormone Therapy (HT).